Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

158.16 -3.00 (-1.86%)
Streaming Delayed Price Updated: 12:16 PM EDT, Apr 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia. 
Via Benzinga
Exposures Product Safety
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
The companies could soon face off in the growth treatment market for children with a genetic disorder. 
Via Investor's Business Daily
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
Via Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow... 
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today
Via Benzinga
$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
Via Benzinga
Why Ascendis Pharma Stock Tumbled by 11% Today
A bottom-line whiff and reduced guidance made the company an outlier for the wrong reasons on Hump Day. 
Via The Motley Fool
Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout
Shares are poised to undercut their 50-day and 200-day lines, and the lower boundary of a base. 
Via Investor's Business Daily
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company... 
Via Benzinga
Core & Main Reports Downbeat Results, Joins Rev Group, PagerDuty, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
Via Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient... 
Via Benzinga
Exposures Product Safety
Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug
The company faced a number of regulatory setbacks that pushed its initial expected approval date out from April. 
Via Investor's Business Daily
Exposures Product Safety
Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
U.S. stock futures rise, Macy's receives higher offer, LGI Homes sells 571 homes, Telefonaktiebolaget records impairment charge, GFL declares dividend. 
Via Benzinga
(ASND) - Analyzing Ascendis Pharma's Short Interest
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
Via Benzinga
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to... 
Via Benzinga
Exposures Product Safety
$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Via Benzinga
ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024
Ascendis Pharma just reported results for the first quarter of 2024. 
Via InvestorPlace
Looking Into Ascendis Pharma's Recent Short Interest
Via Benzinga
Masters In Trading - Saturday, May 11
In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week. 
Via Talk Markets
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Via Benzinga
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
Via Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.